Role of secondary hormonal therapy in the management of recurrent prostate cancer

Charles Ryan, Eric J. Small

Research output: Contribution to journalReview articlepeer-review

37 Scopus citations


Androgen ablation remains the cornerstone of the systemic management of prostate cancer. After initial androgen deprivation, clinical outcomes vary considerably. For the patient with progressive disease after androgen deprivation, multiple therapeutic options are available and include antiandrogen withdrawal, chemotherapy, and secondary hormonal agents. Multiple secondary hormonal agents have clinical activity and the sequential use of these agents may lead to prolonged periods of clinical response. In addition to the use of oral antiandrogens, active secondary hormonal therapies include adrenolytic agents such as ketoconazole and aminoglutethimide, corticosteroids and estrogenic compounds. This article reviews the clinical trial data for these various agents and discusses their role in the management of patients with advanced prostate cancer.

Original languageEnglish (US)
Pages (from-to)87-94
Number of pages8
Issue numberSUPPL. 1
StatePublished - Jan 1 2003
Externally publishedYes


Dive into the research topics of 'Role of secondary hormonal therapy in the management of recurrent prostate cancer'. Together they form a unique fingerprint.

Cite this